CIPLA QUALITY CHEMICAL INDUSTRIES LTD |
End-of-day quote
Other stock markets
|
||
| - UGX | - |
|
| Sales 2022 | 267B 70.33M | Sales 2023 | 221B 58.25M | Capitalization | 219B 57.63M |
|---|---|---|---|---|---|
| Net income 2022 | 24.05B 6.33M | Net income 2023 | 18.99B 4.99M | EV / Sales 2022 | 1.28 x |
| Net Debt 2022 | 17.52B 4.61M | Net cash position 2023 | 5.29B 1.39M | EV / Sales 2023 | 0.97 x |
| P/E ratio 2022 |
13.5
x | P/E ratio 2023 |
11.5
x | Employees | - |
| Yield 2022 |
2.25% | Yield 2023 |
4.17% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ajay Kumar Pal
CEO | Chief Executive Officer | - | 20-02-29 |
| Founder | 62 | - | |
| Director of Finance/CFO | - | 20-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stevens Mwanje
BRD | Director/Board Member | - | - |
Mark Daly
BRD | Director/Board Member | 44 | 18-04-13 |
| Founder | 62 | - |
Cipla Quality Chemicals Industries Limited specializes in the manufacture and marketing of WHO prequalified drugs for the treatment of malaria, retrovirus-related infections and hepatitis B and C. Net sales break down by product family as follows:
- drugs anti-malarial (77.2%);
- drugs antiretroviral (22.4%);
- drugs for the treatment of hepatitis B (0.1%);
- other (0.3%).
At the end of March 2020, the group had a production site in Uganda.
Uganda accounts for 86,9% of net sales.
Sector
-
- Stock Market
- Equities
- CQCIL Stock
